Results 151 to 160 of about 82,620 (274)

Differentiating reactive and neoplastic gamma‐delta (γδ) T‐cell expansions in the peripheral blood and bone marrow

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract The clinical and immunophenotypic attributes of reactive γδ T‐cell expansions are less well characterized than their malignant counterparts, which can pose diagnostic challenges. This study aims to investigate the characteristics and long‐term clinical outcomes of reactive γδ T‐cell expansions.
Hamza Tariq   +6 more
wiley   +1 more source

Clinical validation of a real‐time machine learning‐based system for the detection of acute myeloid leukemia by flow cytometry

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Machine‐learning (ML) models in flow cytometry have the potential to reduce error rates, increase reproducibility, and boost the efficiency of clinical labs. While numerous ML models for flow cytometry data have been proposed, few studies have described the clinical deployment of such models.
Lauren M. Zuromski   +10 more
wiley   +1 more source

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

open access: yesEuropean Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo   +22 more
wiley   +1 more source

A meta‐analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis

open access: yesBritish Journal of Clinical Pharmacology, Volume 89, Issue 1, Page 61-79, January 2023., 2023
Aims In immune‐mediated inflammatory diseases (IMIDs), early symptom control is a key therapeutic goal. Methotrexate (MTX) is the first‐line treatment across IMIDs. However, MTX is underutilized and suboptimally dosed, partly due to the inability of making individualized treatment decisions through therapeutic drug monitoring (TDM). To implement TDM in
Maartje M. van de Meeberg   +10 more
wiley   +1 more source

T Cell Helper Defect in Patients with Chronic Lymphocytic Leukemia [PDF]

open access: bronze, 1979
Nicholas Chiorazzi   +5 more
openalex   +1 more source

A T chronic lymphocytic leukemia with large granular lymphocytes phenotype and functions of leukemic cells under in vitro treatment by differentiation inducers [PDF]

open access: bronze, 1987
Hélène Merle‐Béral   +9 more
openalex   +1 more source

Home - About - Disclaimer - Privacy